Literature DB >> 8643097

Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells.

M Itokawa1, M Toru, K Ito, H Tsuga, K Kameyama, T Haga, T Arinami, H Hamaguchi.   

Abstract

The short (D2S) and long (D2L) isoforms of dopamine D2 receptors were stably expressed in Chinese hamster ovary cells, and dopamine-induced sequestration was examined by measuring the loss of binding of the hydrophilic ligand [3H]sulpiride from the cell surface. Dopamine treatment of Chinese hamster ovary cells expressing D2S for 30 min at 37 degrees caused a 43.8 +/- 3.4% decrease in [3H]sulpiride binding activity measured by incubation of the treated cells with [3H]sulpiride at 4 degrees for 4 hr after the dopamine was washed out. The half-life of the decrease in binding was estimated to be 18.7 +/- 1.6 min, and the concentration of dopamine giving a half-maximal effect (EC50) was estimated to be 180 +/- 90 nM. The decrease was reversible, and the binding activity was recovered by washing out the dopamine and incubating the cells at 37 degrees for 30 min but was not reversible when the cells were incubated at 4 degrees. The binding activity of [3H]spiperone, a hydrophobic ligand, was not affected by the dopamine treatment under the same experimental conditions. These results indicate that approximately one half of the D2S receptors undergo agonist-induced sequestration, probably endocytosis, in a reversible and temperature-dependent manner. Sequestration of D2L receptors was not as apparent as that of D2S receptors; the decrease in [3H]sulpiride binding activity was 21.6 +/- 0.9% and the rate of the decrease was delayed, with a half-life of 33.2 +/- 7.8 min, although effective concentrations of dopamine were similar, with EC50 = 170 +/- 50 nM. A D2S receptor variant containing a missense mutation changing Ser311 in the third intracellular loop to cysteine was found to be sequestered to a significantly lesser extent than with wild-type D2S receptors. This finding was discussed with respect to the report that this variant gene is found more frequently in schizophrenic patients than in control subjects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8643097

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

3.  A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding.

Authors:  Hongxiang Lan; Yong Liu; Michal I Bell; Vsevolod V Gurevich; Kim A Neve
Journal:  Mol Pharmacol       Date:  2008-09-22       Impact factor: 4.436

4.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

5.  Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor.

Authors:  Cecilea C Clayton; Prashant Donthamsetti; Nevin A Lambert; Jonathan A Javitch; Kim A Neve
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

Review 6.  Positron emission tomography in Parkinson's disease: insights into impulsivity.

Authors:  Adam J Stark; Daniel O Claassen
Journal:  Int Rev Psychiatry       Date:  2017-12-05

7.  Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration.

Authors:  P Barbier; A Colelli; R Maggio; D Bravi; G U Corsini
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 8.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

9.  An intracellular loop 2 amino acid residue determines differential binding of arrestin to the dopamine D2 and D3 receptors.

Authors:  Hongxiang Lan; Martha M Teeter; Vsevolod V Gurevich; Kim A Neve
Journal:  Mol Pharmacol       Date:  2008-09-26       Impact factor: 4.436

10.  Nigrostriatal and Mesolimbic D2/3 Receptor Expression in Parkinson's Disease Patients with Compulsive Reward-Driven Behaviors.

Authors:  Adam J Stark; Christopher T Smith; Ya-Chen Lin; Kalen J Petersen; Paula Trujillo; Nelleke C van Wouwe; Hakmook Kang; Manus J Donahue; Robert M Kessler; David H Zald; Daniel O Claassen
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.